Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-Daily Stereotactic Body Radiotherapy Clear all
Active, not recruiting Phase 2 Interventional Results available

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT05500092
View directory record Official record
Conditions
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions
Nivolumab, (8gy x 3), Platinum Doublet
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
4
States / cities
St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Withdrawn Not applicable Interventional

MRI Adaptive Replanning Using ViewRay

NCT02950792
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ViewRay MRI, Stereotactic Body Radiation Therapy Boost
Device · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 4, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00960999
View directory record Official record
Conditions
Lung Cancer
Interventions
Single-fraction stereotactic body radiation therapy (SBRT), Multiple-fraction stereotactic body radiation therapy (SBRT)
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
35
States / cities
Auburn, California • Berkeley, California • Cameron Park, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 4, 2026, 10:12 PM EDT
Active, not recruiting Phase 1 Interventional

Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer

NCT03223155
View directory record Official record
Conditions
Stage IV Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

NCT04789486
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Interventions
AGuIX, Radiotherapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Recruiting Phase 2 Interventional

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

NCT07126158
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Cancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer
Interventions
Stereotactic body radiotherapy, Defactinib, Avutometinib
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Terminated Not applicable Interventional

Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer

NCT05224869
View directory record Official record
Conditions
Prostate Cancer
Interventions
Medical Device Usage and Evaluation, CT simulation, Stereotactic body radiation therapy, Brachytherapy, Post-implant dosimetry scan
Device · Procedure · Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 4, 2026, 10:12 PM EDT
Recruiting Phase 2 Interventional

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

NCT05384496
View directory record Official record
Conditions
Mucosal Melanoma
Interventions
Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Active, not recruiting Phase 1 Interventional

Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer

NCT04073745
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Positive Surgical Margin, Resected Mass, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Other · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Recruiting Phase 2 Interventional

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

NCT05068232
View directory record Official record
Conditions
Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer
Interventions
Ablative Radiation, Durvalumab, Etoposide, Carboplatin
Radiation · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07552558
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Interventions
Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
Radiation · Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Withdrawn Phase 1 Interventional

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

NCT02868632
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MEDI4736, Tremelimumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 4, 2026, 10:12 PM EDT
Terminated Early Phase 1 Interventional

Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma

NCT02319889
View directory record Official record
Conditions
Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer
Interventions
Stereotactic Body Radiotherapy, Carboplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Radiation · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 4, 2026, 10:12 PM EDT
Not listed Phase 1 Interventional

An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT01711697
View directory record Official record
Conditions
Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
stereotactic body radiation therapy, carboplatin, paclitaxel, radiation therapy
Radiation · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 4, 2026, 10:12 PM EDT
Terminated Not applicable Interventional

Daily vs. Non-Daily SBRT for NSCLC

NCT03624907
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Daily Stereotactic Body Radiotherapy, Non-Daily Stereotactic Body Radiotherapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 4, 2026, 10:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

NCT07594522
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Photon or Proton standard stereotactic body radiotherapy (SBRT), Ivonescimab
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Recruiting Not applicable Interventional

Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

NCT07276438
View directory record Official record
Conditions
Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy, Inter-fraction Adaptation of Treatment Plan, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy, Survey Administration
Procedure · Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

GTX-RT in Borderline Resectable Pancreatic Cancer

NCT01754623
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Gemcitabine, Docetaxel, Stereotactic body radiation therapy (SBRT), Restaging review after radiation, Surgery, 5-Fluorouracil
Drug · Radiation · Other + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 4, 2026, 10:12 PM EDT
Recruiting Phase 1 Interventional

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT06141031
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
TTI-101, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Withdrawn Phase 2 Interventional

Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB

NCT03146039
View directory record Official record
Conditions
Cervical Cancer, Cervical Cancer Stage, Cervical Cancer Stage IB2, Cervical Cancer Stage IB1, Cervical Cancer Stage I, Cervical Cancer Stage IB, Cervical Cancer Stage II, Cervical Cancer Stage IIa, Cervical Cancer, Stage IIB, Cervical Cancer, Stage III, Cervical Cancer Stage IIIB, Cervical Cancer Stage IIIA, Cervical Cancer Stage Iv, Cervical Cancer Stage IVA, Cervical Cancer Stage IVB
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 4, 2026, 10:12 PM EDT
Terminated Phase 1 Interventional

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

NCT02400814
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Anti-PD-L1 Monoclonal Antibody MPDL3280A, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 4, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

Metformin in Non Small Cell Lung Cancer (NSCLC)

NCT02285855
View directory record Official record
Conditions
Lung Cancer
Interventions
Metformin, Placebo, Stereotactic body Radiotherapy (SBRT)
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 4, 2026, 10:12 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases

NCT06065449
View directory record Official record
Conditions
Bone Metastases
Interventions
Radiation Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 4, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma

NCT00983541
View directory record Official record
Conditions
Cancer
Interventions
Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
Drug · Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 4, 2026, 10:12 PM EDT